Search clinical trials for: AMD11070

Total 65 results

National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

HIV Infections

United States
Genzyme, a Sanofi Company

Completed

A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus

HIV Infections | X4 Tropic Virus

United States, United Kingdom
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
X4 Pharmaceuticals

Completed

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

Australia, United States
X4 Pharmaceuticals

Active, not recruiting

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

United States, Denmark, Australia, Austria, France, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Russian Federation, Spain, Turkey
X4 Pharmaceuticals

Completed

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma (X4P-001-MELA)

Melanoma

United States
Genzyme, a Sanofi Company

No longer available

This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. (EAP)

Multiple Myeloma | Non-Hodgkin's Lymphoma | Hodgkin's Disease
Emory University
Genzyme, a Sanofi Company

Completed

Alteration in Timing of Plerixafor Administration

Autologous Transplantation

United States
The First Hospital of Jilin University

Active, not recruiting

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Relapsed Adult AML | Relapsed Adult ALL

China
NYU Langone Health
National Institutes of Health (NIH); Genzyme, a Sanofi Company

Withdrawn

Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers (AMD3100)

Diabetic Ulcer

United States
Children's Hospital Medical Center, Cincinnati
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100

Fanconi Anemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Healthy Volunteers

United States
First Affiliated Hospital, Sun Yat-Sen University
Baxter Healthcare Corporation

Recruiting

Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis

Peritoneal Dialysis

China
Mitchell Horwitz, MD
Genzyme, a Sanofi Company

Completed

Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

Failure of Bone Marrow Graft

United States
University of Padova
Azienda Ospedaliera di Padova

Completed

Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects

Diabetes

Italy
Emory University

Terminated

AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia (BMTAMD3100)

Pediatric Acute Myeloblastic Leukemia, Relapsed | Pediatric Acute Lymphoblastic Leukemia, Relapsed

United States
University of Washington
National Heart, Lung, and Blood Institute (NHLBI); Genzyme, a Sanofi Company; George Papanicolaou Hospital

Completed

Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major

Beta-Thalassemia

Greece
University of Washington

Completed

AMD 3100 for Treatment of Myelokathexis

Neutropenia

United States
Emory University
Genzyme, a Sanofi Company

Completed

Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection

Lymphoma | Myeloma

United States
Genzyme, a Sanofi Company
AnorMED

Terminated

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Multiple Myeloma

United States
Genzyme, a Sanofi Company

Completed

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

Renal Impairment

United States
Genzyme, a Sanofi Company

Completed

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

Germany
National Heart, Lung, and Blood Institute (NHLBI)

Completed

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

Healthy

United States
University of Florida

Completed

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Multiple Myeloma | Non-Hodgkin's Lymphoma

United States
Genzyme, a Sanofi Company

Approved for marketing

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization (CUP)

Autologous Stem Cell Transplant
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

Lymphoma, Non-Hodgkin | Multiple Myeloma

Canada
Genzyme, a Sanofi Company
AnorMED

Withdrawn

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia
Genzyme, a Sanofi Company

Terminated

AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

Multiple Myeloma | Lymphoma, Non-Hodgkin's

United States
Duke University
Genzyme, a Sanofi Company

Completed

Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

Multiple Myeloma | Non-Hodgkins Lymphoma | Hodgkins Disease

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
St. Jude Children's Research Hospital
Genzyme, a Sanofi Company

Completed

A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
Seattle Children's Hospital
Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics...

Completed

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

AML | Acute Leukemia of Ambiguous Lineage | ALL | Relapsed/Refractory AML | Relapsed/Refractory ALL | Secondary AML/MDS

United States, Canada
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Hodgkin's Disease

United States
Washington University School of Medicine

Completed

Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Genzyme, a Sanofi Company

Completed

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Autologous Stem Cell Transplantation

United States
Washington University School of Medicine

Completed

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

Stem Cell Transplant Patients

United States
Galderma R&D

Completed

PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK (SESAME 2)

Actinic Keratoses

Germany
Reproductive Medicine Associates of New Jersey

Terminated

Endometrial Rejuvenation Study

Infertility of Uterine Origin

United States
Washington University School of Medicine

Completed

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Multiple Myeloma | Hodgkin Disease | Leukemia, Myelogenous, Chronic | Leukemia, Lymphoblastic, Acute | Lymphocytic Leukemia, Chronic

United States
Washington University School of Medicine

Completed

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies

Hematologic Neoplasms

United States
Proteonomix, Inc.
University of Medicine and Dentistry of New Jersey; Numoda

Unknown

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease

End Stage Liver DIsease

United States
Massachusetts General Hospital
Merck Sharp & Dohme LLC; AperiSys, Inc

Withdrawn

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Genzyme, a Sanofi Company

Completed

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Lymphoma | Multiple Myeloma | Non Hodgkin's Lymphoma | Hodgkin's Disease

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Genzyme, a Sanofi Company; American Association...

Completed

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Washington University School of Medicine

Completed

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Multiple Myeloma | Hodgkin Disease | Leukemia, Lymphocytic, Chronic, B-Cell

United States
Sanofi
Genzyme, a Sanofi Company

Completed

An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells

Multiple Myeloma

Sweden, Estonia, Belgium, Lithuania
Genzyme, a Sanofi Company

Completed

Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).

Non-Hodgkin's Lymphoma | Autologous Transplantation

Search clinical trials for: AMD11070

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations